Dermata Therapeutics (DRMA) Stock Price, News & Analysis

Company Overview

Dermata Therapeutics, Inc. is a clinical‐stage biotechnology company dedicated to developing targeted therapies for inflammatory skin disorders. Leveraging a proprietary intracellular delivery platform, the company aims to address the underlying mechanisms of diseases such as atopic dermatitis, hidradenitis suppurativa and autoimmune blistering disorders. Dermata’s research and development efforts focus on small-molecule and peptide candidates designed to modulate key inflammatory pathways directly within skin cells.

Since its founding, Dermata has advanced a pipeline of product candidates through preclinical studies and early‐stage clinical trials. Lead programs include an intradermal injectable designed to resolve acute inflammation in chronic skin diseases and a topical formulation targeting barrier dysfunction in eczema patients. The company also collaborates with academic institutions and industry partners to strengthen its discovery engine and accelerate the progression of novel assets toward the clinic.

Headquartered in the Boston, Massachusetts area, Dermata Therapeutics serves patient populations in North America and Europe, with plans to expand into additional therapeutic markets as its pipeline matures. The company evolved from earlier life‐science ventures and underwent a strategic rebranding to align its corporate identity with its dermatology focus. Dermata maintains a network of research laboratories and manufacturing partners to support its preclinical and clinical development activities.

Dermata’s executive leadership team brings together experts in dermatological research, drug development and regulatory affairs. Through collaborations with key opinion leaders and patient advocacy groups, the company seeks to address unmet needs in skin disease treatment and improve outcomes for patients worldwide. Dermata continues to leverage its specialized platform technology to create new opportunities for targeted intervention in complex inflammatory skin conditions.

Key Stats

• Today's Range: $0.69 to $0.78
• 50-Day Range: $0.59 to $0.91
• 52-Week Range: $0.57 to $5.00
• Volume: 168,566 shs
• Average Volume: 1.18 million shs
• Market Capitalization: $4.53 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.00
• Consensus Rating: Buy

Dermata Therapeutics Stock Analysis - MarketRank™

Dermata Therapeutics scored higher than 45% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Dermata Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Dermata Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Dermata Therapeutics is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Dermata Therapeutics is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Dermata Therapeutics has a P/B Ratio of 1.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.34% of the float of Dermata Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Dermata Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Dermata Therapeutics has recently decreased by 1.32%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Dermata Therapeutics does not currently pay a dividend.

Dividend Growth

Dermata Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.34% of the float of Dermata Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Dermata Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Dermata Therapeutics has recently decreased by 1.32%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.52

News Sentiment

Dermata Therapeutics has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.00 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Dermata Therapeutics this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Dermata Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

18.50% of the stock of Dermata Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 8.67% of the stock of Dermata Therapeutics is held by institutions.

DRMA Stock Analysis - Frequently Asked Questions

How have DRMA shares performed this year?

Dermata Therapeutics' stock was trading at $1.35 on January 1st, 2025. Since then, DRMA stock has decreased by 47.4% and is now trading at $0.71.

How were Dermata Therapeutics' earnings last quarter?

Dermata Therapeutics, Inc. (NASDAQ:DRMA) posted its earnings results on Wednesday, May, 14th. The company reported ($0.45) earnings per share for the quarter, meeting the consensus estimate of ($0.45).

When did Dermata Therapeutics' stock split?

Dermata Therapeutics's stock reverse split on Thursday, May 16th 2024.The 1-15 reverse split was announced on Thursday, May 16th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 16th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

When did Dermata Therapeutics IPO?

Dermata Therapeutics (DRMA) raised $18 million in an initial public offering on Friday, August 13th 2021. The company issued 2,571,428 shares at $7.00 per share.

How do I buy shares of Dermata Therapeutics?

Shares of DRMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Dermata Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Dermata Therapeutics investors own include BIOLASE (BIOL), CNS Pharmaceuticals (CNSP), Esports Entertainment Group (GMBL), Jiuzi (JZXN), Kiora Pharmaceuticals (KPRX), ENDRA Life Sciences (NDRA) and Sonnet BioTherapeutics (SONN).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 7/11/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:DRMA
• CIK: 1853816
• Web: www.dermatarx.com
• Phone: 858-800-2543
• Fax: N/A
• Employees: 8
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Dermata Therapeutics: $3.00
• High Price Target: $3.00
• Low Price Target: $3.00
• Potential Upside/Downside: +322.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($16.41)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$12.29 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -270.81%
• Return on Assets: -179.96%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.70
• Quick Ratio: 3.70

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.62 per share
• Price / Book: 1.15

Miscellaneous

• Outstanding Shares: 6,380,000
• Free Float: 5,198,000
• Market Cap: $4.53 million
• Optionable: Not Optionable
• Beta: 0.54